ReviewFrontiers in immunology2026
Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a group of chronic immune-mediated inflammatory disease characterize by persistent inflammation of the gastrointestinal tract that can substantially impact quality of life. Due to the inconsistencies and adverse effects associated with conventional therapies, there is an increasing demand for safer and more reliable treatment alternatives for IBD. The pathogenesis of IBD involves multiple factors, including the overactivation of signaling pathways, elevated pro-inflammatory cytokine levels, dysbiosis of the gut microbiota, and activation of immune cells. Traditionally, ginseng has been used as both a dietary component and a therapeutic agent, its bioactive constituents (ginsenosides and their derivatives) have demonstrated potential therapeutic effects in preclinical IBD models. Numerous studies have shown that ginsenosides may ameliorate experimental colitis through multiple mechanisms, including the inhibition of inflammatory signaling pathways, regulation of cytokine production, modulation of immune cell activity, and alteration of the gut microbiota. However, clinical studies investigating the use of ginsenosides in the treatment of IBD are extremely limited. In this review, we provide a comprehensive overview of IBD pathology and highlight the therapeutic potential of ginseng and its derivatives, particularly ginsenosides, as emerging therapeutic option, along with their current challenges and prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.